Opioid rotation in the management of chronic pain: Where is the evidence?

Pain Practice

Volumn 10, Issue 2, 2010, Pages 85-93

  Vissers, K C P ^a   Besse, K ^a   Hans, G ^b   Devulder, J ^c   Morlion, B ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chronic pain; Equianalgesic potency; Opioid; Opioid rotation; Opioid switch

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OPIATE AGONIST; OXYCODONE; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ADD ON THERAPY; ANALGESIA; CANCER PAIN; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; EVALUATION; EVIDENCE BASED PRACTICE; HEART ARRHYTHMIA; HUMAN; HYPERALGESIA; INFORMATION; PAIN; PATIENT SELECTION; PHARMACODYNAMICS; PRESCRIPTION; RESPIRATION DEPRESSION; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; CHRONIC DISEASE; DISEASE MANAGEMENT; MEDLINE; STATISTICS; TREATMENT OUTCOME;

ANALGESICS; ANALGESICS, OPIOID; CHRONIC DISEASE; DISEASE MANAGEMENT; DRUG PRESCRIPTIONS; HUMANS; PAIN; PUBMED; TREATMENT OUTCOME;

EID: 77954738315     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2009.00335.x     Document Type: Review

References (68)

1. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms 1994, 2nd, ed., Seattle, WA, IASP Press
2. Wilson KE. Psychological implications of chronic pain. Practical Management of Pain 2000, 316-332. Raj P. ed., 3rd, ed., St. Louis, MO, Mosby Inc
3. Rosomoff HL, Rosomoff RS. Low back pain. Evaluation and management in the primary care setting. Med Clin North Am 1999, 83:643-662.
4. Sullivan MD, Turner JA, Romano J. Chronic pain in primary care. Identification and management of psychosocial factors. J Fam Pract 1991, 32:193-199.
5. Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. Spine 1995, 20:1878-1883.
6. Jacobson L, Mariano AJ. General Considerations of Chronic Pain 2001, Philadelphia, PA, Lippincott Williams & Wilkins
7. Tait RC, Chibnall JT. Physician judgments of chronic pain patients. Soc Sci Med 1997, 45:1199-1205.
8. Walsh DA, Radcliffe JC. Pain beliefs and perceived physical disability of patients with chronic low back pain. Pain 2002, 97:23-31.
9. Turk DC, Rudy TE, Stieg RL. The disability determination dilemma: toward a multiaxial solution. Pain 1988, 34:217-229.
10. Waddell G. 1987 Volvo award in clinical sciences. A new clinical model for the treatment of low-back pain. Spine 1987, 12:632-644.
11. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977, 196:129-136.
12. Waddell G. Models of Disability: Using Low Back Pain as an Example 2002, London, Royal Society of Medicine Press
13. Cancer Relief, with a Guide to Opioïd Availability 1996, 13-15. WHO, WHO Guideline, 2nd, ed., Geneva, Switzerland, WHO
14. Kalso E, Allan L, Dellemijn PL. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003, 7:381-386.
15. Recommendations for the Appropriate Use of Opioids for Persistent Non-Cancer Pain 2004, Royal College of A, Royal College of GP, Royal College of P, London, The Pain Society
16. Hope-Simpson RE. Post-herpetic neuralgia. J R Coll Gen Pract 1975, 25:571-575.
17. Foley KM. The treatment of cancer pain. N Engl J Med 1985, 313:84-95.
18. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999, 353:1695-1700.
19. Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994, 23:160-170.
20. Dellemijn PLI. Opioids in non-cancer pain: a life-time sentence? Eur J Pain 2001, 5:333-339.
21. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003, 26:1026-1048.
22. Chou R, Fanciullo GJ, Fine PG. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130.
23. Compton P, Athanasos P. Chronic pain, substance abuse and addiction. Nurs Clin North Am 2003, 38:525-537.
24. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008, 11:S133-S153.
25. Martini L, Whistler JL. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 2007, 17:556-564.
26. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009, 65:121-139.
27. Ueda H, Inoue M, Mizuno K. New approaches to study the development of morphine tolerance and dependence. Life Sci 2003, 74:313-320.
28. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag 2008, 4:123-130.
29. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain 2008, 24:469-478.
30. Smith HS. Variations in opioid responsiveness. Pain Physician 2008, 11:237-248.
31. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003, 349:1943-1953.
32. Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain 2007, 11:823-830.
33. Swanson G, Smith J, Bulich R, New P, Shiffman R. Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Oncol 1989, 7:1903-1908.
34. Drexel H, Dzien A, Spiegel RW. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989, 36:169-176.
35. Enting RH, van der Rijt CC, Wilms EB, Lieverse PJ, de Wit R, Smitt PA. Treatment of pain in cancer with systemically administered opioids. Ned Tijdschr Geneeskd 2001, 145:950-954.
36. Cohen SP, Dragovich A. Intrathecal analgesia. Med Clin North Am 2007, 91:251-270.
37. Deer T, Krames ES, Hassenbusch SJ. Polyanalgesic consensus conference 2007: recomendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007, 10:300-328.
38. Koulousakis A, Kuchta J, Bayarassou A, Sturm V. Intrathecal opioids for intractable pain syndromes. Acta Neurochir Suppl 2007, 97:43-48.
39. McNicol E, Horowicz-Mehler N, Fisk RA. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003, 4:231-256.
40. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995, 82:1226-1236.
41. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004, 3:CD004847.
42. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain 2003, 19:286-297.
43. Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs 2001, 5:163-165.
44. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992, 49:87-91.
45. Hanks GW, Conno F, Cherny N. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001, 84:587-593.
46. Pergolizzi J, Boger RH, Budd K. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8:287-313.
47. Lipowski A, Carr D. Re-thinking opioid equivalence. IASP Newsletter 2002, 10:1-10.
48. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999, 86:1856-1866.
49. McMahon S, Koltzenburg M. Wall and Melzack's Textbook of Pain 2005, 5th, ed., Philadelphia, PA, Churchill Livingstone
50. Pijn bij kanker. Landelijke richtlijn. 2008, 1-168. http://www.oncoline.nl, Landelijke richtlijnwerkgroep Pijn bij kanker, In: Landelijke richtlijnwerkgroep Pijn bij kanker, ed., URL
51. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005, 27:225-237.
52. Berger A, Hoffman DL, Goodman S, Delea TE, Seifeldin R, Oster G. Therapy switching in patients receiving long-acting opioids. Ann Pharmacother 2004, 38:389-395.
53. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995, 10:287-291.
54. Cherny NJ, Chang V, Frager G. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995, 76:1283-1293.
55. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995, 10:378-384.
56. Kloke M, Rapp M, Bosse B, Kloke O. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 2000, 8:479-486.
57. Muller-Busch HC, Lindena G, Tietze K, Woskanjan S. Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain 2005, 9:571-579.
58. Riley J, Ross JR, Rutter D. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006, 14:56-64.
59. Morita T, Takigawa C, Onishi H. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage 2005, 30:96-103.
60. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract 2007, 7:123-129.
61. Narabayashi M, Saijo Y, Takenoshita S. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol 2008, 38:296-304.
62. Wirz S, Wartenberg HC, Elsen C, Wittmann M, Diederichs M, Nadstawek J. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial. Clin J Pain 2006, 22:770-775.
63. Cruciani RA. Methadone: to ECG or not to ECG. That is still the question. J Pain Symptom Manage 2008, 36:545-552.
64. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998, 16:3216-3221.
65. Gonzalez-Barboteo J, Porta-Sales J, Sanchez D, Tuca A, Gomez-Batiste X. Conversion from parenteral to oral methadone. J Pain Palliat Care Pharmacother 2008, 22:200-205.
66. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996, 67:115-119.
67. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 2008, 9:595-612.
68. Mercadante S. Switching to methadone: " ad libitum" or fixed dose ratio? Palliat Med 2004, 18:71. author reply 2